期刊文献+

浅谈案例式教学法在“新药研制与报批”课程中的运用——以“专利悬崖”现象为例 被引量:1

Application of Case Study Method in Teaching the Course of Drug Development and Application Based on Patent Cliff Phenomenon
下载PDF
导出
摘要 目的:选择合适的案例,加深学生对于新药研制流程的认识,提高课程的教学质量。方法:以近期国际制药行业中普遍存在的"专利悬崖"现象为切入点,通过经典实例的选择与剖析,向学生系统讲授其产生的原因及行业的应对之道。结果与结论:通过案例式教学法的合理运用,使得学生对于原理精深、流程复杂的新药研制过程有了立体化、形象化的认知,降低了该课程对于本科生的学习难度,提高了学生的积极性和主动性,取得了良好的教学效果,同也提高了学生对于新药研发事业的兴趣。新药研制流程是药学专业课程体系的重要环节,文章也为这类课程的教学提供了一种全新的思路。 Purpose: enhancing the understanding of the process of drug development and application and the quality of teaching through the selection of proper case. Method: using the patent cliff as the content of case study to help students analyze the reason for this phenomenon and the ways to solve this problem. Result and conclusion: based on the rational application of case study, we achieve the goal that help the students form a lively visualization and better understanding on the complicated process of drug development and application. We also stimulate the initiative and the interest of students in learning this course. Considering that the process of drug development is one of the most important node in the curriculum system of pharmacy education,the method can provide us a new strategy for the teaching of Drug Development and Application.
出处 《江苏科技信息》 2016年第15期43-45,48,共4页 Jiangsu Science and Technology Information
基金 江苏高校优势学科建设工程资助项目 项目名称:江苏高校品牌专业建设工程资助项目 项目编号:PPZY2015A070 南京中医药大学教育教学改革2015年度课题 项目名称:"新药研制与报批"全新教学内容与模式的探索和实践 项目编号:NZYZYX2015-09
关键词 案例式教学 新药研制 专利悬崖 case study new drug research and development patent cliff
  • 相关文献

参考文献6

二级参考文献60

  • 1董丽,杨悦.美国药品专利期延长与市场独占期规定研究[J].中国医药导刊,2006,8(5):391-392. 被引量:20
  • 2COHEN WM, NELSON RR, WALSH PJ, et al. Protecting theirintellectual assets: appropriability conditions and why U. S. man-ufacturing firms patent (or Not) [ R ]. NBER Working Paper,2000:7552.
  • 3USPTO. Patent Term Extensions [ EB/OL]. [2012 - 06]. ht-tp ://www. uspto. gov/patents/resources/terms/156. jsp.
  • 4NEROTH P. Protecting profits [ J ] . Lancet, 2004 , ( 364 ):1207 - 1208.
  • 5DWIVED1 G, SHARANABASAVA H,LATHA R. Evergree-ning : a deceptive device in patent rights[ J]. Technol Soc,2010,32:324 -330.
  • 6GOLDFARB B. Claritin approval marks significant shift in Rx-To-OTC swithes[ EB/OL ]. [ 2012 -06]. http ://brucegoldfarb.com/FDL3. pdf.
  • 7FDA. Drug research and children[ EB/OL]. (2011 -08 -24).http ://www. fda. gov/ Drugs/ ResourcesForYou/ Consumers/ ucml43565.htm. utm__ campaign = Google2&utm _ source = fdaSearch&utm _medium = website&utm _ term = PEDIATRIC% 20STUDIES%200F% 20DRUGS&utm_content =7.
  • 8CLARK AM , HEIDI B. The face of the patent is not the ' WholeStory” : determining effective life of a pharmaceutical patent in theUnited States [ J ]. World Pat Information,2004, (26) :283 - 295.
  • 9ANGELL M. The truth about the drug companies: how they de-ceive us and what to do about it [ M ]. New York : RandomHouse,2004:130.
  • 10JOHN AP. How companies can preserve market dominance afterpatents expire[ J]. Long Range Planning,2006 ,(39):71 - 87.

共引文献49

同被引文献15

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部